Purinergic receptors, prostacyclin and atherosclerosis
- 30 September 1992
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 26 (2) , 123-129
- https://doi.org/10.1016/s1043-6618(05)80125-2
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- The role of nitric oxide and cGMP in platelet adhesion to vascular endotheliumPublished by Elsevier ,2005
- Is there a basis for distinguishing two types of P2-purinoceptor?Published by Elsevier ,2002
- P2 purinoceptors on vascular endotheliai cells: physiological significance and transduction mechanismsTrends in Pharmacological Sciences, 1990
- Actions mediated by P2‐purinoceptorsubtypes in the isolated perfused mesenteric bed of the ratBritish Journal of Pharmacology, 1988
- Isolation and washing of human platelets with nitric oxideThrombosis Research, 1988
- ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUMPublished by Elsevier ,1987
- The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxideBritish Journal of Pharmacology, 1987
- Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in plateletsBritish Journal of Pharmacology, 1987
- Endothelium‐derived relaxing factor inhibits in vitro platelet aggregationBritish Journal of Pharmacology, 1987
- Endothelium‐dependent inhibition of platelet aggregationBritish Journal of Pharmacology, 1986